Baseline olfactory impairment, poor performance on cognitive test, and medial temporal lobe atrophy are considered biomarkers for predicting future cognitive decline in dementia-free older adults. However, the combined effect of these predictors has not been fully investigated.
Methods
A group of 110 participants without dementia were continuously recruited into this study, and underwent olfactory, cognitive tests and MRI scanning at baseline and 5-year follow-up. Olfactory function was assessed using the University of Pennsylvania Smell Identification Test (UPSIT). Participants were divided into the cognitive decliners and non-decliners.
Results
Among 87 participants who completed the 5-year follow-up, cognitive decline was present in 32 cases and 55 remained stable. Compared with non-decliners, cognitive decliners presented lower scores on both the UPSIT and the Montreal Cognitive Assessment (MoCA), and smaller hippocampal volume at baseline (all P < .001). The logistic regression analysis revealed that lower scores on UPSIT and MoCA, and smaller hippocampal volume were strongly associated with subsequent cognitive decline, respectively (all P < .001). For the prediction of cognitive decline, lower score on UPSIT performed the sensitivity of 63.6% and specificity of 81.2%, lower score on MoCA with the sensitivity of 74.5% and specificity of 65.6%, smaller hippocampal volume with the sensitivity of 70.9% and specificity of 78.1%, respectively. Combining three predictors resulted in the sensitivity of 83.6% and specificity of 93.7%.
Conclusions
The combination of olfactory test, cognitive test with structural MRI may enhance the predictive ability for future cognitive decline for dementia-free older adults.
JaroudiWGaramiJGarridoSHornbergerMKeriSMoustafaAA. Factors underlying cognitive decline in old age and Alzheimer's disease: the role of the hippocampus. Rev Neurosci. 2017;28(7):705-714.
2.
JongsiriyanyongSLimpawattanaP. Mild cognitive impairment in clinical practice: a review article. Am J Alzheimers Dis Other Demen. 2018;33(8):500-507.
3.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet. 2021;397(10284):1577-1590.
4.
DjordjevicJJones-GotmanMDe SousaKChertkowH. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2008;29(5):693-706.
5.
WangQChenBZhongX, et al.Olfactory dysfunction is already present with subjective cognitive decline and deepens with disease severity in the alzheimer's disease spectrum. J Alzheimers Dis. 2021;79(2):585-595.
6.
ChenBWangQZhongX, et al.Structural and functional abnormalities of olfactory-related regions in subjective cognitive decline, mild cognitive impairment, and alzheimer's disease. Int J Neuropsychopharmacol. 2022;25(5):361-374.
7.
WenCBiYLHuH, et al.Association of subjective cognitive decline with cerebrospinal fluid biomarkers of alzheimer's disease pathology in cognitively intact older adults: the CABLE study. J Alzheimers Dis. 2022;85(3):1143-1151.
8.
ChenZXieHYaoLWeiY. Olfactory impairment and the risk of cognitive decline and dementia in older adults: a meta-analysis. Braz J Otorhinolaryngol. 2021;87(1):94-102.
9.
RobertsROChristiansonTJKremersWK, et al.Association between olfactory dysfunction and amnestic mild cognitive impairment and alzheimer disease dementia. JAMA Neurol. 2016;73(1):93-101.
10.
WilsonRSSchneiderJAArnoldSETangYBoylePABennettDA. Olfactory identification and incidence of mild cognitive impairment in older age. Arch Gen Psychiatry. 2007;64(7):802-808.
11.
DevanandDPLeeSManlyJ, et al.Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology. 2015;84(2):182-189.
12.
DinticaCSMarsegliaARizzutoD, et al.Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. Neurology. 2019;92(7):e700-e709.
13.
OlofssonJKLarssonMRoaCWilsonDAJonsson LaukkaE. Interaction between odor identification deficit and APOE4 predicts 6-year cognitive decline in elderly individuals. Behav Genet. 2020;50(1):3-13.
14.
WindonMJKimSJOhESLinSY. Predictive value of olfactory impairment for cognitive decline among cognitively normal adults. Laryngoscope. 2020;130(4):840-847.
15.
FischerMECruickshanksKJSchubertCR, et al.Age-related sensory impairments and risk of cognitive impairment. J Am Geriatr Soc. 2016;64(10):1981-1987.
16.
AdamsDRKernDWWroblewskiKEMcClintockMKDaleWPintoJM. Olfactory dysfunction predicts subsequent dementia in older U.S. Adults. J Am Geriatr Soc. 2018;66(1):140-144.
17.
McDonaldCRGharapetianLMcEvoyLK, et al.Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging. 2012;33(2):242-253.
18.
SunWHuangLChengY, et al.Medial temporal atrophy contributes to cognitive impairment in cerebral small vessel disease. Front Neurol. 2022;13:858171.
19.
ApostolovaLGMosconiLThompsonPM, et al.Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging. 2010;31(7):1077-1088.
20.
OttoyJNiemantsverdrietEVerhaegheJ, et al.Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging. Neuroimage Clin. 2019;22:101771.
21.
NguyenXVCandemirSErdalBSWhiteRDPrevedelloLM. Predicting mental decline rates in mild cognitive impairment from baseline MRI volumetric data. Alzheimer Dis Assoc Disord. 2021;35(1):1-7.
22.
ValotassiouVMalamitsiJPapatriantafyllouJ, et al.SPECT and PET imaging in Alzheimer's disease. Ann Nucl Med. 2018;32(9):583-593.
23.
RisacherSLSaykinAJ. Neuroimaging in aging and neurologic diseases. Handb Clin Neurol. 2019;167:191-227.
24.
CovaIMeleFZeriniF, et al.The Clock Drawing Test as a predictor of cognitive decline in non-demented stroke patients. J Neurol. 2022;269(1):342-349.
25.
PerronARousselMWannepain-DespretzS, et al.In individuals with subjective cognitive decline, age, memory and speed scores at baseline predict progression to cognitive impairment. Alzheimer Dis Assoc Disord. 2022;36(4):359-361.
26.
DevanandDPLiuXTabertMH, et al.Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry. 2008;64(10):871-879.
27.
KamravaSKFarhadiMJalessiM, et al.University of Pennsylvania smell identification on Iranian population. Iran Red Crescent Med J. 2014;16(1):e7926.
28.
AlotaibiMLessard-BeaudoinMBuschK, et al.Olfactory dysfunction associated with cognitive decline in an elderly population. Exp Aging Res. 2022;16.
29.
PereiroAXRamos-LemaSJuncos-RabadánOFacalDLojo-SeoaneC. Normative scores of the Cambridge cognitive examination-revised in healthy Spanish population. Psicothema. 2015;27(1):32-39.
30.
SohrabiHRBatesKAWeinbornMG, et al.Olfactory discrimination predicts cognitive decline among community-dwelling older adults. Transl Psychiatry. 2012;2(5):e118.
31.
TeipelSJCavedoEGrotheMJ, et al.Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. Neuropharmacology. 2016;108:128-135.
KorolevIOSymondsLLBozokiACAlzheimer's Disease Neuroimaging Initiative. Predicting progression from mild cognitive impairment to alzheimer's dementia using clinical, MRI, and plasma biomarkers via probabilistic pattern classification. PLoS One. 2016;11(2):e0138866.
34.
LojkowskaWSawickaBGugalaM, et al.Follow-up study of olfactory deficits, cognitive functions, and volume loss of medial temporal lobe structures in patients with mild cognitive impairment. Curr Alzheimer Res. 2011;8(6):689-698.
35.
GravesABBowenJDRajaramL, et al.Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status. Neurology. 1999;53(7):1480-1487.
36.
BathiniPBraiEAuberLA. Olfactory dysfunction in the pathophysiological continuum of dementia. Ageing Res Rev. 2019;55:100956.
37.
PriceJLMcKeelDWJr.BucklesVD, et al.Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026-1036.
38.
BraakHBraakE. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271-278.
39.
PriceJLDavisPBMorrisJCWhiteDL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991;12(4):295-312.
40.
DevanandDPLiuXChungaRE, et al.Odor identification impairment and change with cholinesterase inhibitor treatment in mild cognitive impairment. J Alzheimers Dis. 2020;75(3):845-854.
41.
JackCRJr.KnopmanDSJagustWJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
42.
Fennema-NotestineCMcEvoyLKHaglerDJJr.JacobsonMWDaleAMThe Alzheimer's Disease Neuroimaging Initiative. Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behav Neurol. 2009;21(1):3-12.
43.
ZhuLYShiLLuoYLeungJKwokT. Brain MRI biomarkers to predict cognitive decline in older people with alzheimer's disease. J Alzheimers Dis. 2022;88(2):763-769.
44.
PiniLPievaniMBocchettaM, et al.Brain atrophy in Alzheimer's Disease and aging. Ageing Res Rev. 2016;30:25-48.
45.
McEvoyLKHollandDHaglerDJJr., et al.Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology. 2011;259(3):834-843.
46.
JosephsKAMurrayMETosakulwongN, et al.Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol. 2017;133(5):705-715.
47.
DevanandDPPradhabanGLiuX, et al.Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007;68(11):828-836.
48.
GrundmanMSencakovaDJackCRJr., et al.Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002;19(1-2):23-27.
49.
DaweRJYuLArfanakisKSchneiderJABennettDABoylePA. Late-life cognitive decline is associated with hippocampal volume, above and beyond its associations with traditional neuropathologic indices. Alzheimers Dement. 2020;16(1):209-218.
50.
DevanandDPLeeSLuchsingerJA, et al.Intact global cognitive and olfactory ability predicts lack of transition to dementia. Alzheimers Dement. 2020;16(2):326-334.
51.
JiaXWangZHuangF, et al.A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry. 2021;21(1):485.
